58130-38-4

Basic information

• Product Name: 5-AMINO-3,4-DIHYDROQUINOLIN-2(1H)-ONE
• Synonyms: 5-AMINO-3,4-DIHYDROQUINOLIN-2(1H)-ONE;5-aMino-1,2,3,4-tetrahydroquinolin-2-one;5-amino-3,4-dihydro-2(1H)-Quinolinone;5-amino-3,4-dihydro-1H-quinolin-2-one
• CAS NO: 58130-38-4
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• EINECS: 604-604-1
• Mol File: 58130-38-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 135.5 °C
• Boiling Point: 395.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.47±0.20(Predicted)
• CAS DataBase Reference: 5-AMINO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(58130-38-4)
• EPA Substance Registry System: 5-AMINO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(58130-38-4)

Safety Data

• Hazardous Substances Data: 58130-38-4(Hazardous Substances Data)

Usage

General Description

5-Amino-3,4-dihydroquinolin-2(1H)-one is a chemical compound that belongs to the quinolinone family. It is a synthetic intermediate used in the production of pharmaceuticals and agrochemicals. The compound contains an amino group and a dihydroquinolinone ring structure, which makes it a versatile building block for the synthesis of various bioactive molecules. It is commonly used as a starting material in the synthesis of potential drug candidates and research chemicals. Its unique structure and reactivity make it a valuable tool in the field of organic synthesis and drug discovery.

Upstream product

• 6938-27-8 5-nitro-2<1H>quinolinone 
• 65887-63-0 5-nitro-3,4-dihydro-1H-quinolin-2-one 
• 606-31-5 2,6-dinitrobenzaldehyde 
• 24623-25-4 4-nitro-2,3-dihydro-1H-inden-1-one 
• 108128-36-5 4-nitro-indan-1-one oxime 

Downstream Products

• 72995-15-4 5-chloro-3,4-dihydro-2(1H)-quinolinone 
• 81839-35-2 5-[4-(4-Nitrobenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril 
• 81849-95-8 5-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril 
• 81839-71-6 5-[4-(4-nitrobenzyl)-1-piperazinyl]-3,4-dihydrocarbostyril 
• 81840-30-4 5-[4-(4-cyanobenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril 
• 292143-15-8 5-(6,6-dimethyl-hept-2-en-4-ynylamino)-3,4-dihydro-1H-quinolin-2-one 
• 260369-80-0 5-benzylideneamino-3,4-dihydro-2(1H)-quinolinone 
• 1393130-42-1 C₁₈H₁₉N₃O₂*ClH 
• 1393130-40-9 C₂₅H₂₅N₃O₂*ClH 
• 260369-81-1 5-benzylideneamino-1-(3-chloropropyl)-3,4-dihydro-2(1H)-quinolinone 
• 1369534-93-9 (2E,4Z)-5-(4-isopropoxyphenyl)-N-(2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-(4-trifluoromethylphenyl)-2,4-pentadienamide 
• 1002125-84-9 (2E,4Z)-5-(4-ethoxyphenyl)-N-(2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-(4-trifluoromethylphenyl)-2,4-pentadienamide 

Relevant articles and documents

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition

A series of novel bicyclic 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl] piperazines was synthesized and evaluated on binding to dopamine D2 receptors and serotonin reuptake sites. This class of compounds proved to be potent in vitro dopamine D2 receptor antagonists and in addition were highly active as serotonin reuptake inhibitors. Some key representatives showed potent pharmacological in vivo activities after oral dosing in both the antagonism of apomorphine-induced climbing and the potentiation of 5-HTP-induced behavior in mice. On the basis of the preclinical data, 8-{4-[3-(5-fluoro-1H- indol-3-yl)propyl]piperazin-1-yl}-4H-benzo[1,4]oxazin-(R)-2-methyl-3-one (45c, SLV314) was selected for clinical development. In vitro and in vivo studies revealed that 45c has favorable pharmacokinetic properties and a high CNS plasma ratio. Molecular modeling studies showed that the bifunctional activity of 45c can be explained by its ability to adopt two different conformations fitting either the dopamine D2 receptor pharmacophore or the serotonin transporter pharmacophore.